← Back to Search

Antimetabolites

Carboplatin for Gastroesophageal Cancer

Phase 1

Waitlist Available

Led By Theodore S. Hong, MD

Research Sponsored by Massachusetts General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial is studying how well the combination of these interventions work in treating GE junction cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The Completion Rate of Chemotherapy in Combination With Chemoradiation

Secondary outcome measures

Clinical Response Rate

Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

Overall Survival

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: FOLFIRINOX + pre-operative radiationExperimental Treatment7 Interventions

FOLFIRINOX is a combination of 4 drugs that is administered twice per cycle Oxaliplatin is administered intravenously Leucovorin is administered intravenously Irinotecan is administered intravenously 5-Fluorouracil is administered intravenously Paclitaxel and Carboplatin will be given concurrently with radiation therapy every 7 days

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Carboplatin

FDA approved

Leucovorin

FDA approved

Irinotecan

FDA approved

Oxaliplatin

FDA approved

Radiation Therapy

2017

Completed Phase 3

~7250

Fluorouracil

FDA approved

Paclitaxel

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,654 Previous Clinical Trials

40,933,128 Total Patients Enrolled

Massachusetts General HospitalLead Sponsor

2,928 Previous Clinical Trials

13,198,330 Total Patients Enrolled

Theodore S. Hong, MDPrincipal InvestigatorMassachusetts General Hospital

10 Previous Clinical Trials

750 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To which maladies is Carboplatin typically applied?

"Carboplatin is traditionally used to alleviate macrocytic anemia, but it may also be effective at treating neoplasm metastasis, lymphoma, non-Hodgkin's disease or advanced stages of non-small cell lung cancer."

Answered by AI

Are there any other studies that have utilized Carboplatin as a key component?

"As of now, 1704 clinical trials are being conducted on Carboplatin. Of these studies, 503 are in the advanced Phase 3 stage. Guangzhou and Guangdong host a majority of them but there is still research taking place at 88922 other locations worldwide."

Answered by AI

Are there still opportunities for participants to join in this research?

"This clinical trial has completed its recruitment process. It was initially posted on October 24th 2017 and last updated on September 7th 2022. As of now, there are 26 other trials recruiting patients with gastroesophageal cancer, as well as 1704 studies involving Carboplatin that need participants."

Answered by AI

To what degree does Carboplatin pose a risk to patients?

"In comparison to other treatments, the safety of carboplatin has not been extensively studied. Our team at Power estimates its safety rating as a 1 on a scale from 1-3 due to it being in Phase 1 trials."

Answered by AI

What is the scope of recruitment for this trial's participants?

"At present, this trial is not in the recruitment phase. It was first posted on October 24th2017 and last updated on September 7th 2022. Alternatively, those searching for clinical trials with a focus on gastroesophageal cancer can find 26 actively recruiting studies while 1704 are enrolling patients for Carboplatin treatment."

Answered by AI

Recent research and studies

Clinical Cancer ResearchJournal

Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas

Wo, Jennifer Y., Jeffrey W. Clark, Christine E. Eyler, Mari Mino-Kenudson, Samuel J. Klempner, Jill N. Allen, Florence K. Keane, et al.. 2021. “Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas”. Clinical Cancer Research. American Association for Cancer Research (AACR). doi:10.1158/1078-0432.ccr-21-0331.

clinicaltrials.govStudy

A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers

Theodore Sunki Hong 2017. "A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03279237.